Sugi Predict

Sugi Predict / Compounds / SCHEMBL4154837

SCHEMBL4154837

SCHEMBL4154837

Nc1ccc2nc3ccccc3c(N)c2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.72
▸ ALDH1A1 P00352 4/20 0.72
▸ GLA P06280 4/20 0.72
▸ HPGD P15428 4/20 0.72
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ ACHE P22303 3/20 0.72
▸ CASP1 P29466 2/20 0.72
▸ CASP7 P55210 2/20 0.72
▸ HSD17B10 Q99714 2/20 0.72
▸ CHRM2 P08172 1/20 0.72
▸ ADRA2A P08913 1/20 0.72
▸ ADORA3 P0DMS8 1/20 0.72
▸ CHRM1 P11229 1/20 0.72
▸ NQO2 P16083 1/20 0.72
▸ MAOA P21397 1/20 0.72
▸ DRD1 P21728 1/20 0.72
▸ SLC6A2 P23975 1/20 0.72
▸ ADRA1A P35348 1/20 0.72
▸ OPRM1 P35372 1/20 0.72
▸ KCNH2 Q12809 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28959157 0.98 RAB9A (0.73) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL4163642 0.88 KDM4E (0.72) KDM4EALDH1A1GLAHPGDSMN1; SMN2
SCHEMBL25757979 0.86 KMT2A (0.64) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL29354393 0.85 HSD17B10 (1.00) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL14999 0.85 HSD17B10 (1.00) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Proflavine SCHEMBL10534144 0.85 HTR3A (0.72) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL635597 0.83 RAB9A (1.00) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL18989123 0.83 HSD17B10 (0.95) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL4907467 0.83 HSD17B10 (0.95) KDM4EALDH1A1GLAHPGDSMN1; SMN2
Aminacrine SCHEMBL14482032 0.83 HSD17B10 (0.95) KDM4EALDH1A1GLAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230040324-A1 AMINOACRIDINE AND AMINOPYRENE DYES AND THEIR USE AS FLUORESCENT TAGS, IN PARTICULAR FOR CARBOHYDRATE ANALYSIS MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E. V. (DE) 2023-02-09 — — US disclosed
EP-4069784-A1 AMINOACRIDINE AND AMINOPYRENE DYES AND THEIR USE AS FLUORESCENT TAGS, IN PARTICULAR FOR CARBOHYDRATE ANALYSIS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2022-10-12 — — EP disclosed
WO-2021110280-A1 AMINOACRIDINE AND AMINOPYRENE DYES AND THEIR USE AS FLUORESCENT TAGS, IN PARTICULAR FOR CARBOHYDRATE ANALYSIS Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) 2021-06-10 — — WO disclosed
US-9127164-B2 Fluorescent dyes and uses thereof ALMAC SCIENCES (SCOTLAND) LIMITED (GB) 2015-09-08 — — US disclosed
US-9127164-B2 Fluorescent dyes and uses thereof ALMAC SCIENCES (SCOTLAND) LIMITED (GB) 2015-09-08 — — US disclosed
US-9127164-B2 Fluorescent dyes and uses thereof ALMAC SCIENCES (SCOTLAND) LIMITED (GB) 2015-09-08 — — US disclosed
EP-1940965-B1 NOVEL FLUORESCENT DYES AND USES THEREOF ALMAC SCIENCES SCOTLAND LTD (GB) 2014-03-26 — — EP disclosed
EP-1940965-B1 NOVEL FLUORESCENT DYES AND USES THEREOF ALMAC SCIENCES SCOTLAND LTD (GB) 2014-03-26 — — EP disclosed
US-20090226940-A1 NOVEL FLUORESCENT DYES AND USES THEREOF ITI SCOTLAND LIMITED (GB) 2009-09-10 — — US disclosed
US-20090226940-A1 NOVEL FLUORESCENT DYES AND USES THEREOF ITI SCOTLAND LIMITED (GB) 2009-09-10 — — US disclosed
US-20090226940-A1 NOVEL FLUORESCENT DYES AND USES THEREOF ITI SCOTLAND LIMITED (GB) 2009-09-10 — — US disclosed
EP-1940965-A2 NOVEL FLUORESCENT DYES AND USES THEREOF ITI Scotland Limited (GB) 2008-07-09 — — EP disclosed
WO-2007049057-A2 NOVEL FLUORESCENT DYES AND USES THEREOF ITI SCOTLAND LIMITED (GB) 2007-05-03 — — WO disclosed
WO-2007049057-A2 NOVEL FLUORESCENT DYES AND USES THEREOF ITI SCOTLAND LIMITED (GB) 2007-05-03 — — WO disclosed
US-20040053966-A1 Chemical derivatives and their application as antitelomerase agent AVENTIS PHARMS S.A. 2004-03-18 — — US disclosed
US-6645964-B1 1,3,5-Triazine compounds substituted with aromatic N-heterocycle; anticarcinogenic agents AVENTIS PHARMA S.A. (FR) 2003-11-11 — — US disclosed
EP-1244650-B1 ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT AVENTIS PHARMA SA (FR) 2003-06-25 — — EP disclosed
EP-1244650-A1 ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT Aventis Pharma S.A. (FR) 2002-10-02 — — EP disclosed
WO-2001040218-A1 ARYLAMINE DERIVATIVES AND THEIR USE AS ANTI-TELOMERASE AGENT AVENTIS PHARMA S.A. (FR) 2001-06-07 — — WO disclosed
US-4462993-A REACTION WITH A SUGAR IN PRESENCE OF ACID CATALYST BIOGAL GYOGYSZERGYAR (HU) 1984-07-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226940-A1 NOVEL FLUORESCENT DYES AND USES THEREOF ACR, ANXA5, GLB1 KDM4E 4255/4885ALDH1A1 97/4885GLA 30/4885
US-20040053966-A1 Chemical derivatives and their application as antitelomerase agent NTPCR, DPYD, NME1 KDM4E 2750/4885ALDH1A1 506/4885GLA 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.